Ionic Loading in Bcl-2 Family Inhibitor Liposomes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for therapeutically effective Bcl-2 family inhibitor compositions that do not cause dose-limiting thrombocytopenia, tumor lysis syndrome, or other unacceptable side effects, and for improved methods of delivering Bcl-2 family inhibitors, particularly through liposomal formulations that enhance sustained release and reduce toxicity.
Innovation Solution
Liposomal compositions are developed with a lipid bilayer, internal medium containing a loading aid, and Bcl inhibitors encapsulated within the internal medium, which can include polymer-conjugated lipids and ionic loading aids, to enhance encapsulation efficiency and reduce adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Bcl-2 family inhibitors are administered to achieve therapeutic effect, then cancer treatment efficacy is improved, but dose-limiting thrombocytopenia and tumor lysis syndrome occur
Solution Approach 1:
Liposomes serve as intermediary carriers to deliver Bcl-2 family inhibitors to target cells. The liposomal formulation encapsulates the drug, enabling selective delivery to cancer cells while protecting normal cells from toxic effects. This mediator approach resolves the contradiction by separating the therapeutic action from systemic toxicity.
Solution Approach 2:
The invention achieves localized drug delivery to cancer cells through liposomal targeting. The drug concentration is highly concentrated at the tumor site while maintaining low systemic levels, creating local high-quality therapeutic effect without widespread harmful effects. This local quality approach allows high efficacy at the target while minimizing systemic side effects.
2Ease of manufacture
If passive loading is used to encapsulate drugs in liposomes, then loading process is simple, but encapsulation efficiency and functional-compound-to-lipid ratio are low
Solution Approach 1:
The invention applies preliminary action by pre-forming liposomes with specific properties before drug loading. The liposomes are prepared in advance with optimized composition and structure, then drugs are loaded into these pre-prepared carriers. This preliminary preparation enables both simple loading procedures and high encapsulation efficiency, resolving the contradiction between ease of manufacture and manufacturing precision.
3Productivity
If drugs are loaded into the lipid bilayer for passive loading, then loading efficiency is improved, but drug release from liposome is very rapid
Solution Approach 1:
The invention uses nested doll strategy by placing drugs inside the liposomal aqueous core rather than in the lipid bilayer. This nested structure provides an additional containment layer, enabling both efficient loading and sustained release. The drug is nested within the liposome interior, protecting it from rapid release while maintaining high loading capacity.
Solution Approach 2:
The liposomal membrane acts as a flexible shell that controls drug release kinetics. The bilayer membrane provides a controlled barrier that allows sustained drug release over time while maintaining high loading efficiency. This flexible shell structure resolves the contradiction by enabling both efficient encapsulation and prolonged release duration.
4Reliability
If Bcl-2 family inhibitors are administered at high doses to overcome resistance, then therapeutic effect is improved, but unacceptable side effects increase
Solution Approach 1:
Liposomes act as intermediaries that deliver high concentrations of Bcl-2 family inhibitors directly to cancer cells while maintaining low systemic drug levels. This mediator approach enables achieving high therapeutic effect at the target site without exposing the whole body to high drug doses, thus avoiding unacceptable side effects.
Solution Approach 2:
The invention creates local quality by concentrating the drug effect specifically at the tumor site through liposomal targeting. High drug concentrations are achieved locally in cancer cells to overcome resistance, while systemic drug levels remain low to avoid unacceptable side effects. This local quality differentiation resolves the contradiction between therapeutic effect and side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The liposomal formulations achieve high encapsulation efficiency, sustained drug release, reduced toxicity, and lower dosing frequency while minimizing thrombocytopenia and other adverse events, thereby improving therapeutic efficacy.
Implementation Method 1
Passive loading of lipophilic and to a lesser extent amphiphilic functional compounds is somewhat more efficient than hydrophilic functional compounds because they partition in both the lipid bilayer and the intraliposomal (internal) aqueous medium
Implementation Method 2
For sustained release of the drug in a patient it is preferable that the drug is encapsulated within the interior of the liposome
Data Source
AI summary
Provided herein are liposomes comprising B-cell lymphoma (Bcl) protein inhibitors, compositions comprising such liposomes, and methods using such formulations for treating hyperproliferative disorders.